Oncology Institute, Inc. (NASDAQ:STLN - Get Free Report) Director Brad Hively sold 298,853 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the sale, the director directly owned 411,976 shares of the company's stock, valued at $2,681,963.76. This represents a 42.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oncology Institute Price Performance
Shares of STLN stock opened at $6.13 on Tuesday. Oncology Institute, Inc. has a 12 month low of $2.32 and a 12 month high of $7.05.
Oncology Institute (NASDAQ:STLN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The firm had revenue of $161.28 million for the quarter, compared to analyst estimates of $152.80 million. Sell-side analysts forecast that Oncology Institute, Inc. will post -0.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oncology Institute
A hedge fund recently bought a new stake in Oncology Institute stock. AXQ Capital LP bought a new stake in Oncology Institute, Inc. (NASDAQ:STLN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 22,460 shares of the company's stock, valued at approximately $122,000. 36.86% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, Weiss Ratings assumed coverage on Oncology Institute in a research note on Thursday, August 6th. They set a "sell (d-)" rating for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of "Sell".
Check Out Our Latest Stock Analysis on STLN
About Oncology Institute
(
Get Free Report)
Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.
The company's business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
